newsfilter
← Latest News
Business Wire·

TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

-- SM-88 with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival – TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company dev